Biocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from acquiring Viatris Inc.’s biosimilars business. The company has already prepaid $250 million and is exploring ways to reduce finance costs. The bond’s rating will determine its pricing.
7 investing lessons from Jim Leitner for building the right market mindset
Leitner believes investors should remain open to new ideas and recognise that markets can challenge even experienced participants.
October 3, 2026